| scholarly article | Q13442814 |
| review article | Q7318358 |
| P2093 | author name string | Alexander Brobeil | |
| Monika Wimmer | |||
| Stefan Gattenlöhner | |||
| Eric Dietel | |||
| P2860 | cites work | VAPB interacts with the mitochondrial protein PTPIP51 to regulate calcium homeostasis | Q24298739 |
| PTPIP51, a novel 14-3-3 binding protein, regulates cell morphology and motility via Raf-ERK pathway | Q24310359 | ||
| PTPIP51, a positive modulator of the MAPK/Erk pathway, is upregulated in glioblastoma and interacts with 14-3-3β and PTP1B in situ | Q24339410 | ||
| A brake becomes an accelerator: PTP1B--a new therapeutic target for breast cancer. | Q54383166 | ||
| Vemurafenib in Chinese patients with BRAFV600 mutation-positive unresectable or metastatic melanoma: an open-label, multicenter phase I study. | Q54979813 | ||
| MEK inhibition may increase survival of NRAS-mutated melanoma patients treated with checkpoint blockade: Results of a retrospective multicentre analysis of 364 patients | Q56891349 | ||
| Effectiveness of EGFR/HER2-targeted drugs is influenced by the downstream interaction shifts of PTPIP51 in HER2-amplified breast cancer cells | Q58709253 | ||
| PTPIP51 interaction with PTP1B and 14-3-3β in adipose tissue of insulin-resistant mice | Q83297453 | ||
| Improved Risk-Adjusted Survival for Melanoma Brain Metastases in the Era of Checkpoint Blockade Immunotherapies: Results from a National Cohort | Q90007528 | ||
| BRAF V600E mutation and BRAF VE1 immunoexpression profiles in different types of glioblastoma | Q90259754 | ||
| Co-targeting BET and MEK as salvage therapy for MAPK and checkpoint inhibitor-resistant melanoma. | Q52591043 | ||
| Melanoma: What do all the mutations mean? | Q54115719 | ||
| PTPIP51 is phosphorylated by Lyn and c-Src kinases lacking dephosphorylation by PTP1B in acute myeloid leukemia. | Q54376438 | ||
| Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1 | Q24651548 | ||
| Mechanisms of resistance and sensitivity to anti-HER2 therapies in HER2+ breast cancer | Q26772969 | ||
| Insulin receptor signaling in normal and insulin-resistant states | Q26823171 | ||
| An overview on the role of FLT3-tyrosine kinase receptor in acute myeloid leukemia: biology and treatment | Q27027207 | ||
| FLT3 mutations in acute myeloid leukemia: what is the best approach in 2013? | Q27028163 | ||
| Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group | Q27824835 | ||
| Lapatinib plus capecitabine for HER2-positive advanced breast cancer | Q27851403 | ||
| Frequencies of BRAF and NRAS mutations are different in histological types and sites of origin of cutaneous melanoma: a meta-analysis | Q27851617 | ||
| Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene | Q27860693 | ||
| RAS isoforms and mutations in cancer at a glance | Q28070394 | ||
| The hunting of the Src | Q28199081 | ||
| Lyn associates with the juxtamembrane region of c-Kit and is activated by stem cell factor in hematopoietic cell lines and normal progenitor cells | Q28252234 | ||
| Mutations of C-RAF are rare in human cancer because C-RAF has a low basal kinase activity compared with B-RAF | Q28280081 | ||
| MAP kinase signalling pathways in cancer | Q29615542 | ||
| Src family kinases and HER2 interactions in human breast cancer cell growth and survival | Q30307291 | ||
| Epidemiology of Obesity and Diabetes and Their Cardiovascular Complications | Q30388554 | ||
| Protein tyrosine phosphatase interacting protein 51--a jack-of-all-trades protein | Q30400364 | ||
| The surprising dynamics of scaffolding proteins. | Q30409921 | ||
| Epidermal growth factor-receptor activation modulates Src-dependent resistance to lapatinib in breast cancer models | Q30412086 | ||
| Met and c-Src cooperate to compensate for loss of epidermal growth factor receptor kinase activity in breast cancer cells | Q30415408 | ||
| Second messenger systems in human gliomas | Q33301928 | ||
| Epidermal Growth Factor Receptor Cell Proliferation Signaling Pathways | Q33737298 | ||
| Treatment of NRAS-mutated advanced or metastatic melanoma: rationale, current trials and evidence to date | Q33887664 | ||
| Signaling pathways in insulin action: molecular targets of insulin resistance | Q33973814 | ||
| Src, a potential target for overcoming trastuzumab resistance in HER2-positive breast carcinoma | Q34051933 | ||
| How do 14-3-3 proteins work?-- Gatekeeper phosphorylation and the molecular anvil hypothesis | Q34120299 | ||
| MAPK/ERK signaling regulates insulin sensitivity to control glucose metabolism in Drosophila | Q34126334 | ||
| PTP1B: from the sidelines to the front lines! | Q34209253 | ||
| PTPIP51 in protein interactions: regulation and in situ interacting partners | Q34271712 | ||
| The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis | Q34493341 | ||
| Protein tyrosine phosphatase interacting protein 51 (PTPIP51) is a novel mitochondria protein with an N-terminal mitochondrial targeting sequence and induces apoptosis | Q34544761 | ||
| Acute myeloid leukemia: epidemiology and etiology | Q34571533 | ||
| MAPK signal pathways in the regulation of cell proliferation in mammalian cells | Q34593370 | ||
| 14-3-3 eta depletion sensitizes glioblastoma cells to irradiation due to enhanced mitotic cell death | Q39015881 | ||
| The known interactome of PTPIP51 in HaCaT cells—inhibition of kinases and receptors | Q39026639 | ||
| The mitogen-activated protein kinase pathway in melanoma part I - Activation and primary resistance mechanisms to BRAF inhibition. | Q39124064 | ||
| Mechanisms and strategies to overcome resistance to molecularly targeted therapy for melanoma | Q39329582 | ||
| Targeting EGFRvIII for glioblastoma multiforme | Q39397607 | ||
| Role Played by Signalling Pathways in Overcoming BRAF Inhibitor Resistance in Melanoma | Q39434922 | ||
| 14-3-3 proteins are required for maintenance of Raf-1 phosphorylation and kinase activity | Q39575866 | ||
| A critical role for Lyn in acute myeloid leukemia. | Q40040911 | ||
| The Prognostic Value of BRAF, C-KIT, and NRAS Mutations in Melanoma Patients With Brain Metastases. | Q40117357 | ||
| Lyn is an important component of the signal transduction pathway specific to FLT3/ITD and can be a therapeutic target in the treatment of AML with FLT3/ITD. | Q40182148 | ||
| Pro-survival AKT and ERK signaling from EGFR and mutant EGFRvIII enhances DNA double-strand break repair in human glioma cells | Q40323053 | ||
| ALS/FTD-associated FUS activates GSK-3β to disrupt the VAPB-PTPIP51 interaction and ER-mitochondria associations. | Q40991422 | ||
| ER-mitochondria signaling regulates autophagy | Q41138057 | ||
| Melanoma driver mutations and immune therapy | Q42034581 | ||
| The ER-Mitochondria Tethering Complex VAPB-PTPIP51 Regulates Autophagy. | Q42253285 | ||
| Glioma and glioblastoma - how much do we (not) know? | Q42578340 | ||
| Targeting the ERK signaling pathway as a potential treatment for insulin resistance and type 2 diabetes | Q42814401 | ||
| Targeting c-KIT (CD117) by dasatinib and radotinib promotes acute myeloid leukemia cell death. | Q46038713 | ||
| Isoform-specific expression of 14-3-3 proteins in human astrocytoma | Q46319088 | ||
| Estimating progression-free survival in patients with glioblastoma using routinely collected data | Q47909802 | ||
| Targeting FLT3 Mutations in Acute Myeloid Leukemia | Q48278191 | ||
| Protein tyrosine phosphatase 1B deficiency or inhibition delays ErbB2-induced mammary tumorigenesis and protects from lung metastasis | Q34607187 | ||
| Targeting the function of the HER2 oncogene in human cancer therapeutics | Q34766486 | ||
| HER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapies | Q34974436 | ||
| Molecular diagnostics in acute leukemias | Q35007333 | ||
| Molecular targets in acute myelogenous leukemia | Q35029566 | ||
| cAMP activation of PKA defines an ancient signaling mechanism. | Q35576088 | ||
| Adjuvant trastuzumab in HER2-positive breast cancer | Q35710898 | ||
| Association Between NRAS and BRAF Mutational Status and Melanoma-Specific Survival Among Patients With Higher-Risk Primary Melanoma | Q35801085 | ||
| PTPIP51—A New RelA-tionship with the NFκB Signaling Pathway | Q35833989 | ||
| Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience | Q35849204 | ||
| Activation of multiple ERBB family receptors mediates glioblastoma cancer stem-like cell resistance to EGFR-targeted inhibition. | Q36062158 | ||
| Src family kinases differentially influence glioma growth and motility | Q36218089 | ||
| Chromosome aberrations, gene mutations and expression changes, and prognosis in adult acute myeloid leukemia | Q36662150 | ||
| Dysplastic nevi and melanoma | Q36739933 | ||
| Inhibition of the protein tyrosine phosphatase PTP1B: potential therapy for obesity, insulin resistance and type-2 diabetes mellitus | Q37022381 | ||
| Cerebral metastases from malignant melanoma: current treatment strategies, advances in novel therapeutics and future directions. | Q37328281 | ||
| Neratinib overcomes trastuzumab resistance in HER2 amplified breast cancer | Q37381579 | ||
| Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways | Q37425090 | ||
| Glioblastoma: Overview of Disease and Treatment | Q37441791 | ||
| Cell and molecular biology of the novel protein tyrosine-phosphatase-interacting protein 51. | Q37505664 | ||
| The epidermal growth factor receptor as a therapeutic target in glioblastoma multiforme and other malignant neoplasms | Q37550601 | ||
| Clinical implications of c-Kit mutations in acute myelogenous leukemia. | Q37738571 | ||
| Mitogen-Activated Protein (MAP) Kinase Scaffolding Proteins: A Recount. | Q38086019 | ||
| PTP1B: a simple enzyme for a complex world | Q38123537 | ||
| Dasatinib preferentially induces apoptosis by inhibiting Lyn kinase in nilotinib-resistant chronic myeloid leukemia cell line | Q38270029 | ||
| Breast Cancer: Epidemiology and Etiology | Q38301683 | ||
| NRAS-mutant melanoma: current challenges and future prospect | Q38598958 | ||
| Altered Protein Interactions of the Endogenous Interactome of PTPIP51 towards MAPK Signaling | Q38654834 | ||
| Inhibition of PTP1B disrupts cell-cell adhesion and induces anoikis in breast epithelial cells | Q38703993 | ||
| The role of mitogen-activated protein targeting in melanoma beyond BRAFV600. | Q38722861 | ||
| ORP5/ORP8 localize to endoplasmic reticulum-mitochondria contacts and are involved in mitochondrial function. | Q38775367 | ||
| PTPIP51 levels in glioblastoma cells depend on inhibition of the EGF-receptor. | Q38888799 | ||
| Mutation-specific RAS oncogenicity explains NRAS codon 61 selection in melanoma | Q38953667 | ||
| Orchestrating cellular signaling pathways-the cellular "conductor" protein tyrosine phosphatase interacting protein 51 (PTPIP51). | Q38979223 | ||
| ER-mitochondria associations are regulated by the VAPB-PTPIP51 interaction and are disrupted by ALS/FTD-associated TDP-43. | Q38988714 | ||
| P275 | copyright license | Creative Commons Attribution | Q6905323 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 10 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | mitochondrial protein | Q67455737 |
| P577 | publication date | 2018-10-22 | |
| P1433 | published in | International Journal of Molecular Sciences | Q3153277 |
| P1476 | title | The Importance of the Right Framework: Mitogen-Activated Protein Kinase Pathway and the Scaffolding Protein PTPIP51 | |
| P478 | volume | 19 |
| Q90382880 | Mitogen-Activated Protein Kinases: Functions in Signal Transduction and Human Diseases |
| Q92156901 | Reversal of sorafenib resistance in hepatocellular carcinoma: epigenetically regulated disruption of 14-3-3η/hypoxia-inducible factor-1α |
| Q89910913 | The Emerging Role of Rab5 in Membrane Receptor Trafficking and Signaling Pathways |
| Q98164329 | The identification of nuclear αvβ3 integrin in ovarian cancer: non-paradigmal localization with cancer promoting actions |
Search more.